Simvastatin normalizes QTc dispersion and reduces ventricular electrical instability in isolated hypercholesterolemia

Journal of Endocrinological Investigation

Volumn 25, Issue 6, 2002, Pages RC16-RC18

  Gualdiero, P ^a   Esposito, K ^a   Ciotola, M ^a   Marfella, R ^a   Giugliano, Dario ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Cholesterol; QTc dispersion; Simvastatin; Ventricular instability

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; HYPOCHOLESTEROLEMIC AGENT;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; OUTPATIENT DEPARTMENT; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGY; HEART VENTRICLE; MIDDLE AGED; PATHOPHYSIOLOGY;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGY; FEMALE; HEART VENTRICLE; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, HDL CHOLESTEROL; LIPOPROTEINS, LDL CHOLESTEROL; MALE; MIDDLE AGE; PLACEBOS; SIMVASTATIN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; HEART VENTRICLES; HUMANS; MIDDLE AGED;

EID: 0036072205     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03345487     Document Type: Article

References (25)

1. Range of serum cholesterol values in the population developing coronary artery disease
2. Use of lipid lowering drugs for primary prevention of coronary heart disease: Meta-analysis of randomised trials
3. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S)
4. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels (CARE)
5. The long term intervention with pravastatin in ischaemic disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
6. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
7. Sudden cardiac death
8. Circulating non-esterified fatty acids level as a predictive risk factor for sudden death in the population
9. Enalapril reduces QTc dispersion in mild congestive heart failure secondary to coronary artery disease
10. Dispersion of the QT interval in patients with and without susceptibility to ventricular tachyarrhythmias after previous myocardial infarction
11. Dispersion of QT interval and autonomic modulation of heart rate in hypertensive men with and without left ventricular hypertrophy
12. Clinical significance of increased QT dispersion in the 12-lead standard ECG for arrhythmia risk prediction in dilated cardiomyopathy
13. Measuring QT dispersion: Man versus machine
14. An analysis of time-relations of electrocardiograms
15. Cholesterol increases the L-type voltage-sensitive calcium channel current in arterial smooth muscle cells
16. Pinacidil-induced electrical heterogeneity and extrasystolic activity in canine ventricular tissues. Does activation of ATP-regulated potassium current promote phase 2 re-entry?
17. Heterogeneity within the ventricular wall: Electrophysiology and pharmacology of epicardial, endocardial and M cells
18. Slow ventricular activation in acute myocardial infarction: A source of re-entrant premature ventricular contractions
19. Simultaneous recording of action potentials from endocardium and epicardium during ischemia in the isolated cat ventricle. Relation of temporal electrophysiologic heterogeneities to arrhythmias
20. Modulation of coronary vasomotor tone in humans: Progressive endothelial dysfunction with different early stages of coronary atherosclerosis
21. Lipid lowering and plaque regression: New insights into prevention of plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease
22. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without pre-existing cardiovascular disease
23. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase AKT and promotes angiogenesis in normocholesterolemic animals
24. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits
25. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by RHO GTPase